The introduction of the first disease-modifying therapies fundamentally transformed the management of geographic atrophy and ...

Geographic atrophy management could benefit greatly from the combination of novel therapies and AI-driven imaging technology.

Distinct retinal vessel atrophy patterns may be associated with multiple sclerosis (MS), but further research is needed to assess retinal vessel changes and their underlying role in MS. Changes in the ...

ORLANDO -- The PRIMA system combining a subretinal photovoltaic implant and eyeglasses that project near-infrared light to the implant significantly improved vision in patients with geographic atrophy ...

Regardless of dosing regimen, patients treated with ranibizumab had a 43% higher incidence of GA, which was a statistically significant increase compared with bevacizumab. The ranibizumab group had ...

Ocugen, Inc. announced that the Data and Safety Monitoring Board has approved the continuation of the second phase of the Phase 1/2 OCU410 ArMaDa clinical trial for treating geographic atrophy (GA) ...

ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the first European ...

A tiny wireless implant is giving new hope to people blinded by advanced age-related macular degeneration. In a major ...